It was called ‘complement’ because it aided the antibacterial activity of antibodies. However, it is now known that the complement system can be activated early in an infection without the presence of ...

Dianthus achieved its NASDAQ listing last year via a merger with Magenta Therapeutics. The company is focused on development of a single drug candidate, DNTH-103, which targets the complement system, ...